Fig. 3

Changes in the diffusion tensor imaging (DTI) for Cerebrolysin (30 ml/day) and placebo at baseline (Day 8, T0), immediately after treatment (Day 29, T1) and three (Day 90, T3) months after stroke onset. Analysis was based on the intention-to-treat (ITT) population using the last observation carried forward (LOCF) approach for missing data in the subgroup of patients with severe motor impairment (FMA <50). Time courses (1) and changes from baseline (2) are given for the fractional anisotropy (FA; a), the axial diffusivity (AD; b), and the radial diffusivity (RD; c). *p < 0.05 between time points in each group; **p < 0.05 between both groups; ***p < 0.05 between groups over time (repeated measures ANOVA)